Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering by �쑄�쁺�꽠
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 7 0 , N O . 6 , 2 0 1 7
ª 2 0 1 7 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E AM E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
I S S N 0 7 3 5 - 1 0 9 7
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 7 . 0 6 . 0 1 2REVIEW TOPIC OF THE WEEKOvercoming the Roadblocks to Cardiac
Cell Therapy Using Tissue Engineering
Mounica Yanamandala, MD,a Wuqiang Zhu, MD, PHD,b Daniel J. Garry, MD, PHD,c Timothy J. Kamp, MD, PHD,d
Joshua M. Hare, MD,e Ho-wook Jun, PHD,b Young-sup Yoon, MD, PHD,f Nenad Bursac, PHD,g
Sumanth D. Prabhu, MD,h Gerald W. Dorn II, MD,i Roberto Bolli, MD,j Richard N. Kitsis, MD,a Jianyi Zhang, MD, PHDbABSTRACTFro
bD
Ins
Un
Mi
Co
hD
iCe
jIn
No
co
co
MaTransplantations of various stem cells or their progeny have repeatedly improved cardiac performance in animal models
of myocardial injury; however, the beneﬁts observed in clinical trials have been generally less consistent. Some of the
recognized challenges are poor engraftment of implanted cells and, in the case of human cardiomyocytes, functional
immaturity and lack of electrical integration, leading to limited contribution to the heart’s contractile activity and
increased arrhythmogenic risks. Advances in tissue and genetic engineering techniques are expected to improve the
survival and integration of transplanted cells, and to support structural, functional, and bioenergetic recovery of
the recipient hearts. Speciﬁcally, application of a prefabricated cardiac tissue patch to prevent dilation and to
improve pumping efﬁciency of the infarcted heart offers a promising strategy for making stem cell therapy a
clinical reality. (J Am Coll Cardiol 2017;70:766–75) © 2017 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).A lthough transplanted cells and engineeredtissues result in improved cardiac perfor-mance when tested in animal models of
myocardial injury, the beneﬁts observed in clinical
trials have generally been modest at best. Opinions
regarding the optimal cell type or combination of
cell types have yet to reach consensus, and only a
very small proportion of the administered cells are
engrafted by the native myocardium. Cellular attri-
tion is often attributed to a lack of perfusion in the
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AB BR E V I A T I O N S
AND ACRONYM S
CM = cardiomyocyte
CPC = cardiac progenitor cell
Cx43 = connexin 43
EC = endothelial cell
hiPSC = human induced
pluripotent stem cell
HLA = human leukocyte
antigen
hPSC = human pluripotent
stem cell
MHC = major
histocompatibility complex
MI = myocardial infarction
PSC = pluripotent stem cell
TNF = tumor necrosis factor
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767bioenergetic recovery of the infarcted heart. These
and many other topics were discussed by attendees
of the National Institutes of Health 2016 Progenitor
Cell Biology Consortium and Cardiovascular Tissue
Engineering Symposium at the University of Ala-
bama, Birmingham, on March 28, 2016. Here, we pre-
sent some of the more provocative ideas and
advances that were discussed at the meeting and
that may facilitate the translation of cardiac cell-
and tissue-engineering therapies from the laboratory
to the clinic.
CELL TYPES FOR USE IN CARDIAC THERAPY
A wide variety of cell sources have been evaluated for
repair of the ischemic myocardium in animal models,
and a subset of these have undergone testing in
clinical trials. A recent review by Nguyen et al. (1)
summarized the clinical trials on stem cell therapy
for ischemic heart diseases and heart failure from
January 1, 2000, to July 2016. Table 1 adds the new
clinical trials for ischemic heart diseases and heart
failure published between July 27, 2016, and May 18,
2017, based on our PubMed search results, as well as
clinical trials for stem cell therapy for congenital
heart diseases.
Human pluripotent stem cells (hPSCs) and newer
cell types, such as induced cardiac progenitor cells
(CPCs) (2,3), are especially promising for cardiac cell
and tissue engineering therapy (4–6) because they
can be efﬁciently differentiated into functional car-
diomyocytes (CMs), endothelial cells (ECs), and
smooth muscle cells (SMCs) (7–11). However, the
optimal proportions of each cell type have yet to be
identiﬁed, and a variety of other cell lineages (e.g.,
resident CPCs) (12) may be needed to maximize
therapeutic effectiveness. Furthermore, mitochon-
dria have important functions in cardiac metabolism
(13) and programmed CM death (14), and emerging
roles in cardiac differentiation were recently
suggested (15,16). Speciﬁcally, CM differentiation
requires the membranes of adjacent mitochondria to
fuse, and fusion of the outer membranes is regulated
by mitofusins 1 and 2, which direct ESC differentia-
tion into CMs via regulation of calcineurin and Notch
signaling (16).
The importance of restoring functional CMs for
post-infarction repair is self-evident because they
provide the mechanical force needed for contraction.
In a rat model of myocardial infarction (MI),
measurements of cardiac function and remodeling
were signiﬁcantly better when implanted ﬁbrin gel-
based tissue-engineered patches were created from
the complete population of neonatal rat cardiac cellsthan when the CMs were omitted (17).
Furthermore, extracellular matrix production
in tissue-engineered patches appears to in-
crease in response to production of trans-
forming growth factor b1 by CMs (18,19), and
CMs are an important source of vascular
endothelial growth factor in cell sheet–based
engineered tissues (20). Thus, CMs and cy-
tokines that mediate CM–non-CM communi-
cation are crucial components of the
beneﬁcial activity induced by transplanted
engineered cardiac tissues.
Other cell sources of potential utility for
cardiac repair include mesenchymal stem
cells (prototypically derived from bone
barrow), cardiac stem cells, cardiospheres
isolated from endocardial biopsies (in mice
and humans), which are composed of a
heterogeneous cell population, but are exceptionally
proliferative, and Abcg2-expressing progenitor cells
(21). When suspended in saline and transplanted into
the hearts of mice after an acute infarction, Sca-1þ/
CD31 cells appear to attenuate decline in cardiac
function, increase myocardial neovascularization,
and modestly promote CM differentiation from graft
cells, as well as host cell proliferation (22).
Variation of interspecies responses to cell therapy
is another critical issue. Commonly used preclinical
models include nonhuman primates, large mammals
(swine, dog, and others), and rodents. Although it
might be necessary, there is neither guidance on
selection of preclinical animal models nor consensus
criteria on experimental design for preclinical
studies thus far. Genetic background may affect the
interpretation of experimental results. Therefore,
comparison and validation of data collected from
different species are important when translating
preclinical research to clinical trials.
Although transplantation of various cell types has
been reported to improve left ventricular function
and structure after MI, overwhelming evidence has
demonstrated that there is no signiﬁcant long-term
engraftment of adoptively transferred cells into the
host myocardium. The persistence of beneﬁcial
effects, despite the disappearance of transplanted
cells, indicates that cell therapy may act via paracrine
mechanisms. In addition, the rapid clearance of cells
from the host myocardium suggests that the beneﬁts
of cell therapy are limited by the poor engraftment of
the cells, implying that 1 dose does not adequately
test the efﬁcacy of that cell product (23). However,
almost all preclinical and clinical studies of cell
therapy performed heretofore have based their
assessment of efﬁcacy on the outcome of
TABLE 1 Published Stem/Progenitor Cell Clinical Trials for Heart Diseases
Diseases Trial Design Sample Size Cell Type Cell Source Delivery Route
HLHS Nonrandomized (phase 1) 7 Autologous CDC Cardiosphere IC
HLHS Randomized (phase 2) 34 Autologous CDC Cardiosphere IC
Ischemic heart disease Randomized control (phase 2) 90 Autologous BMCs Bone marrow IC vs. IM
Ischemic heart disease Randomized control (phase 3) 271 Autologous MSCs Bone marrow IM
Nonischemic cardiomyopathy Randomized control (phase 2) 22 Allogeneic MSCs Bone marrow IV
Refractory angina Randomized control (phase 2) 31 Autologous CD133þ cells Bone marrow TEP
Ischemic vs. nonischemic
dilated cardiomyopathy
Nonrandomized (phase 1) 27 Autologous skeletal
stem-cell sheets
Skeletal muscle
(vastus medialis)
Sutured to
heart surface
Nonischemic dilated
cardiomyopathy
Randomized (phase 2) 37 Allogeneic MSC (19 patients) vs.
autologous MSC (18 patients)
Bone marrow TEP
STEMI Randomized control (phase 2) 188 Autologous BMCs Bone marrow IC
BMC ¼ bone marrow–derived cell; BNP ¼ B-type natriuretic peptide; CDC ¼ cardiosphere-derived cells; HLHS ¼ hypoplastic left heart syndrome; hMSC ¼ human mesenchymal stem cell; IC ¼ intracoronary
infusion; IM ¼ intramyocardial injection; IV ¼ intravenous; LVEF ¼ left ventricular ejection fraction; MSC ¼ mesenchymal stem cell; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; RVEF ¼ right
ventricular ejection fraction; STEMI ¼ ST-segment elevation myocardial infarction; TEP ¼ transendocardial injection; TNF ¼ tumor necrosis factor.
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modest or no beneﬁcial effects might be overcome by
repeated cell doses. The rationale is that just as most
pharmacological agents are ineffective when given
once, but can be highly effective when given repeat-
edly, a cell product might be ineffective or modestly
effective as a single treatment, but might be quite
efﬁcacious if given repeatedly.
On the basis of preclinical data performed in large
animal models, human testing of various adult cell
sources has progressed from phase I to phase III trials
(24,25). From a mechanistic standpoint, cell therapy
in the iterations described earlier reduces tissue
ﬁbrosis, restores tissue perfusion, has a powerful
anti-inﬂammatory effect, and stimulates myogenesis,
largely by promoting endogenous myogenesis (24).
Moreover, clinical trial activity is extending into
numerous cardiomyopathic disease states, including
hypoplastic left heart syndrome, adriamycin-induced
cardiomyopathy, and idiopathic dilated cardiomyop-
athy. Future efforts to apply tissue-engineering
strategies in the clinical setting will emerge
following appropriate preclinical testing.
CELL ENGRAFTMENT
As many as 1 billion CMs are lost during MI, and
although the typical dose of transplanted cells may
approach or exceed this number, just 0.1% to 10% of
the cells are engrafted into the myocardium and
continue to survive for more than a few weeks after
transplantation (26,27). Much of this attrition can be
attributed to the harsh environment in and near the
region of the infarct; thus, one strategy for improvingengraftment and survival of transplanted cells is to
use natural or artiﬁcial biomaterials that provide a
protective environment for the transplanted cells
(28–30). Overall, published reports indicate that the
functional beneﬁts of the cardiac cell patch therapy
critically depend upon the longer-term structural
integrity of the cell patches. Maintenance of longer-
term graft size remains a major challenge in preclin-
ical trials of cell therapy.
IMMUNOGENICITY
One of the chief beneﬁts of human induced pluripotent
stem cells (hiPSCs) is that they can be generated from a
patient’s own somatic cells, and consequently are not
expected to provoke an immune response after trans-
plantation. Although this approach holds appeal for
avoiding pharmacological immunosuppression and
associated complications, it requires a substantial time
window (months) for hiPSC generation, followed by
differentiation and graft formation. Thus, this autol-
ogous approach is better suited to treatment of more
chronic heart failure with existing technology. How-
ever, some studies suggest that the immune tolerance
of patient-speciﬁc induced PSC–derived cells may vary
depending on the cells’ lineage (31–34). Questions
regarding immunogenicity are often addressed by
performing experiments in mice with humanized im-
mune systems, but the currently available models
have a limited lifespan and inconsistent immune
response, perhaps because the animals’ endogenous
immune system is eliminated with sublethal doses of
radiation. Collectively, these observations suggest
that translation of hiPSC-derived cell technology to
TABLE 1 Continued
Follow-Up
Summary/Observation
Trial Name/IdentiﬁerHeart Function Others
18–36 months [ RVEF Improved somatic growth TICAP/NCT01273857 (78,79)
12 months [ RVEF Reduced ﬁbrosis, improved somatic growth PERSEUS/NCT01829750 (80)
6–12 months [ LVEF in IM group, but not in IC group YNT-proBNP in IM group, but not IC group REGENERATE-IHD/NCT00747708 (81)
39 weeks No change LVEF Y incidence of sudden or aborted sudden deaths CHART-1/NCT01768702 (82)
90 days No change LVEF [ health status and Y circulating inﬂammatory cells NCT02467387 (83)
1, 4, 6, and 12 months No change LVEF Y angina REGENT-VSEL/NCT01660581 (84)
12 months [ LVEF in patients with ischemic heart
diseases, but not in patients with
nonischemic heart diseases
Y BNP in patients with ischemic heart diseases, but
not in patients with nonischemic heart diseases
UMIN000003273 (85)
12 months [ LVEF in allo-MSC group, but not in the
auto-MSC group
Y TNF-a, to a greater extent with allo-hMSCs vs.
auto-hMSCs at 6 months
POSEIDON-DCM/NCT01392625 (24)
6 months [ LVEF in BMC group No treatment effect in irradiated BMC group BOOST-2/ISRCTN17457407 (86)
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769clinical applications will likely require testing of the
immunogenicity of each hiPSC-derived cell lineage in a
new generation of models that can provide more
consistent and reliable results.
Allograft rejection is primarily mediated by
host-derived reactive T lymphocytes that recognize
non-self human leukocyte antigens (HLAs) on the
surface of transplanted donor cells. Humans have 2
main categories of HLAs: major histocompatibility
complex (MHC) classes I and II. The Townes laboratory
recently showed that surface expression of HLA class I
molecules can be largely eliminated in a line of human
embryonic stem cells (H9) using the clustered regu-
larly interspaced short palindromic repeats (CRISPR)/
CRISPR-associated protein (Cas) gene-editing system
to knock out both alleles of the gene for b2 micro-
globulin, which is essential for cell-surface expression
of HLA class I and stability of the peptide-binding
groove. CRISPR/Cas gene editing has also been used
to knock out the Class II MHC transactivator (CIITA) in
human ECs, and the CIITA-knockout ECs could be
transplanted into mice without producing an immune
response (35). The degree of differentiation of the
hiPSCs derivatives engrafted may also inﬂuence the
immunogenicity of the tissue grafts. This is particu-
larly relevant for tissue-engineering applications,
because even when professional antigen-presenting
cells are depleted, cell-mediated allograft rejection
can still occur (36). This is perhaps because human ECs
activate alloantigen-reactive memory CD4þ T cells via
a mechanism requiring expression of class II MHCs.
Thus, gene-editing technologies may enable
researchers to create “universal donor” hiPSC lines, as
well as hiPSC-derived cells and engineered tissues
with substantially higher rates of engraftment that canbe used to treat a wider variety of patients and
diseases.
IMMUNOMODULATION
As described earlier, stem cell engraftment rates and
survival following transplantation are disappoint-
ingly low. Moreover, among surviving transplanted
progenitor cells, the demonstrable magnitude of dif-
ferentiation into functional CMs has been variable,
ranging from no evidence of CM differentiation to
generation of small, apparently integrated CMs
(22,26,37–39). Most studies of cell therapy seek to
intervene therapeutically either after MI or during
chronic heart failure. The proinﬂammatory environ-
ment of the failing heart may also be responsible for
the reported functional beneﬁts of cardiac cell ther-
apies. As both of these pathological scenarios exhibit
heightened inﬂammatory activation and innate and
adaptive immune cell inﬁltration in the myocardium
(40–43), these microenvironmental factors may be
important contributors to the suboptimal responses
to cell therapy. For example, tumor necrosis factor
(TNF), a proinﬂammatory cytokine elaborated by
both immune cells and failing CMs, restrains CM dif-
ferentiation of resident cardiac stem cells, and can
channel an alternate neuroadrenergic-like fate
in vitro (44); these effects would be expected to
diminish the reparative effects of stem cell therapy.
Such ﬁndings suggest that immunomodulation of the
proinﬂammatory microenvironment in recipients of
progenitor cell therapy may be a high-yield strategy
to enhance cell engraftment and CM differentiation.
To date, such approaches have been relatively unex-
plored, but could include targeting speciﬁc innate
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proinﬂammatory macrophages), speciﬁc cytokines
(e.g., TNF), and/or antigen-independent T-cell
responses. These methodologies would be comple-
mentary to the suppression of antigen-dependent
MHC responses described earlier, and would ideally
comprise circumscribed interventions designed to
improve cell engraftment at the time of delivery and
subsequent CM differentiation during initial repair.
Interestingly, mesenchymal stem cells suppress TNF
levels substantially, and this effect may therefore
contribute to some of the positive effects of these
cells in clinical trials (24).
ARRHYTHMOGENESIS
Injected hPSC-derived CMs have not been associated
with arrhythmias in rodents, but when the dose was
scaled up for delivery to nonhuman primates
(macaques), all 4 of the cell-treated animals experi-
enced periods of premature ventricular contractions
and/or ventricular tachycardia (45). These results
were recently conﬁrmed in a larger set of macaques
upon allogeneic transplantation of macaque PSC-
derived CMs suspended in a prosurvival cocktail
(46). The discrepancy between observations in ro-
dents and macaques may have occurred because the
large dose of cells administered to macaques was
accompanied by a dramatic ($10-fold) increase in
tissue graft size. As the action potential passes
through the myocardium, the anatomic and/or func-
tional heterogeneity introduced by these large re-
gions of immature, electrically active tissue may slow
down or partially block conduction, thus setting the
conditions for life-threatening re-entrant arrhythmias
(47). Because they are electrically immature and
contain sinoatrial nodal cells, hPSC CMs possess
autonomous pacemaking activity and consequently,
are capable of ectopic beats that could further pre-
cipitate arrhythmia induction. If exogenous cells
indeed engraft at much higher rate, this may result in
even more severe ventricular arrhythmias. Of note,
compared with human hearts, macaque hearts are
much smaller and their resting rate is much higher,
which raises doubts as to their suitability for pre-
dicting arrhythmogenic risks in humans. Although
larger animals, such as pigs, are a better model of
human heart physiology, objective assessment of
human cell therapies in large animals will require
adequate immunosuppression, which may be easiest
to achieve in nonhuman primates.
In adult mammalian hearts, electrical propagation
and myocardial contractions are coordinatedprimarily through the gap-junction proteins connexin
40, connexin 43 (Cx43), and connexin 45 (48), of
which Cx43 is by far the most abundant. Cx43 is
expressed in both atrial and ventricular myocytes
(49), and deﬁciencies in Cx43 expression or organi-
zation have been linked to development of arrhyth-
mias in patients with heart failure and other
cardiomyopathies (48,50,51). Furthermore, previous
studies (52) suggested that the risk of arrhythmogenic
complications from transplanted cells may decline
substantially if the cells were genetically modiﬁed to
overexpress Cx43. Thus, graft-associated arrhythmo-
genicity may be substantially reduced by using
gene-editing technologies to increase expression of
gap-junction proteins in transplanted CMs or
surrounding nonmyocytes. Still, the small cell size
and immature expression and distribution of ion
channels and gap junctions in transplanted CMs, as
well as the isotropic architecture of the grafts, likely
contributed to the occurrence of arrhythmias in ma-
caques, despite proven host–graft Cx43 coupling
(30,46). Additional experimental and computational
studies are warranted to establish critical structural
and functional properties of transplanted grafts
leading to increased arrhythmia susceptibility.
Furthermore, the results from a recent study (53)
suggest that intramyocardially injected cardiac
microtissue particles (consisting of w1,000 cells/
particle) suspended in prosurvival cocktail produce
grafts that are electrically coupled to the native
myocardium, but an epicardially implanted engi-
neered cardiac tissue patch does not. The combined
use of genetically encoded ﬂuorescent calcium
reporters (e.g., GCaMP) (45,46) targeted to trans-
planted cells and voltage-sensitive dyes with
nonoverlapping emission spectra labeling host
myocardial tissue will be valuable for exploring the
mechanisms of arrhythmogenesis and evaluating the
effectiveness of strategies for improving electrome-
chanical integration of engineered myocardial grafts.
MYOCARDIAL BIOENERGETICS
The contractile activity of engineered myocardial tis-
sue is expected to contribute directly to myocardial
performance, but improvements can also evolve
through the release of cytokines that promote angio-
genesis, activate endogenous progenitor cells (20,54),
or stimulate other beneﬁcial paracrine pathways.
Furthermore, the damage induced by an acute infarct
event is exacerbated by chronic myocardial overload,
dilation, and overstretching, which increase wall
stress and can lead to metabolic abnormalities, such
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771as declines in the rate of adenosine triphosphate
(ATP) use or in the ratio of phosphocreatine to ATP
in surrounding CMs (55–58). These bioenergetic ab-
normalities were largely corrected when hiPSCs were
differentiated into hiPSC-ECs and hiPSC-SMCs, and
then suspended in a ﬁbrin scaffold positioned over the
site of infarction in swine hearts (55). Thus, a consid-
erable amount of the beneﬁt associated with
engineered tissue transplantation may stem from the
structural support of the graft or its cytokine produc-
tion, in addition to direct remuscularization of the
injured region.
ENGINEERED ORGANS
Current limitations of human organ transplants have
prompted researchers to consider use of xenogeneic
organs as an alternative strategy. For example, func-
tional pancreatata composed of rat cells have been
generated in mice by injecting murine blastocysts
with rat PSCs (59), and then transplanting the blas-
tocysts into surrogate mouse dams. Importantly, the
blastocysts could not generate the target organ
because they expressed a mutated form of Pdx1, the
master regulatory gene for pancreatic development,
and consequently provided a niche for the develop-
ment of the wild-type rat organ. This “blastocyst
complementation” strategy has also been used to
produce livers and kidneys in rodents and pan-
creatata in pigs (60–62), whereas members of the
Garry laboratory used an analogous approach that
combined gene editing with somatic cell nuclear
transfer to engineer pig embryos that lacked cardio-
vascular cells, and then rescued this deﬁciency with
wild-type, green ﬂuorescent protein–labeled pig
blastomeres. Although these studies support the
feasibility of generating patient-speciﬁc organs that
can be used as models for preclinical work or,
perhaps, as organs for transplantation therapy, the
utility of this technology will remain limited until
methods for generating organs from human stem cells
become more efﬁcient.
STIMULATING ENDOGENOUS
REGENERATION AND REPAIR
In addition to transplantation of exogenous stem cells
and engineered tissues or organs, the ability to
stimulate endogenous cardiac repair could eventually
lead to development of effective cell-free therapies
for MI. Lower organisms, such as the newt and
zebraﬁsh, as well as neonatal mice, have a tremen-
dous ability to regenerate from severe myocardialinjury (22,63), but the regenerative capacity of adult
mouse and human hearts is much more limited.
Nevertheless, studies that map cell fate or use
radiocarbon dating indicate that both murine and
human CMs are continually replaced, albeit at a very
low rate: an average of w1% of human CMs are newly
formed each year, with roughly one-half of the cells
replaced over a lifetime (59,64). A number of studies
indicate that adult hearts can be remuscularized
through the proliferation and differentiation of c-Kitþ
CPCs, and endogenous CPCs may also release exo-
somes or paracrine factors that modulate the repair
process and promote neovascularization. Neverthe-
less, genetic fate-mapping assessments by van Berlo
et al. (65,66) indicated that although c-Kitþ CPCs can
give rise to CMs, they do so in an extremely limited
fashion. Newly emerging studies are showing that
endogenous repair mechanisms can be dramatically
up-regulated (67).
Furthermore, although the ﬁbroproliferative
response (i.e., scar formation) is beneﬁcial for short-
term stability at the injury site, it interferes with
subsequent repair processes, such as vascular growth
and potentially remuscularization. Thus, researchers
have also begun to investigate methods for control-
ling or reverting ﬁbrosis by reprogramming ﬁbro-
blasts into CMs or ECs (68–70), and by identifying the
cellular source(s) contributing to scar formation
(71,72). The use of tissue-engineered systems may
increase in vitro efﬁcacy and improve understanding
of the direct cardiac reprogramming processes
(73,74), as well as permit well-controlled mechanistic
studies of CM/nonmyocyte interactions (75).
DISPARITY BETWEEN PRECLINICAL
AND CLINICAL STUDY RESULTS
The positive results from studies of cell therapy for
the treatment of MI in small-animal models have
generally not been observed in clinical trials. For
example, results from a phase I clinical trial indicated
that although intracoronary administration of autolo-
gous cardiac sphere-derived stem cells associatedwith
a signiﬁcantly decreased infarction size in patients
with acute MI, left ventricular chamber function did
not improve (76). Many of the factors that determine
the effectiveness of cell- or engineered-tissue–based
therapies likely depend both on the unique charac-
teristics of each speciﬁc disease state and on complex
interactions among numerous mechanisms of action,
but these variables cannot be adequately or safely
explored in clinical investigations. Future tissue-
engineering therapies for MI are expected to face the
CENTRAL ILLUSTRATION Overview of Strategies to Overcome the Roadblocks in Cardiac Cell Therapy
Yanamandala, M. et al. J Am Coll Cardiol. 2017;70(6):766–75.
The delivery of types of cells generally resulted in modest therapeutic beneﬁts. Transplantation of pre-fabricated engineered heart tissue (e.g., cardiac tissue patch
containing pluripotent stem cell–derived tri-cardiac cells) could enhance the therapeutic effects by an increased engraftment rate, which in turn, results in prolonged
release of cytokines, reduction in left ventricular (LV) dilation and LV wall stresses. A major challenge that remains to be addressed is the potential arrhythmia
risks associated with a large graft.
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772same logistic issues. Thus, relevant large-animal
models of myocardial dysfunction are critical for
identifying, characterizing, and quantifying the
physiological response to cell and tissue trans-
plantation therapies, as well as the optimal cell or
biomaterial type, dose, timing, and route of adminis-
tration, to ensure that each patient receives the
maximum possible beneﬁt while avoiding the com-
plications associated with overtreatment.CONCLUSIONS
Although adult bone marrow– or myocardium-derived
progenitors can offer multiple paracrine beneﬁts to
surviving CMs in the infarcted heart, they are unlikely
to contribute to the formation of de novo working
myocardium (77). CMs derived from PSCs can address
this challenge, but are more complicated to use in
autologous therapies and potentially less robust to
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773surviving transplantation. Although the jury for the
optimal cell source is still out, it is possible that
different disease applications will require different
cell types, and that a mixture of immune-matched or
immune-engineered PSC-derived CMs and host-
derived stromal progenitors will prove optimal in
inducing heart remuscularization while supporting
cell survival and engraftment. Notably, applications of
pre-formed engineered cardiac tissue patches with
speciﬁcally tailored cell compositions could signiﬁ-
cantly increase both the survival and the beneﬁcial
effects of transplanted cells. Furthermore, because
paracrine factors, including extracellular vesicles, are
responsible for much of the observed beneﬁcial effects
of cardiac cell therapy, amaintained tissue patch could
serve as a continued source of such beneﬁcial para-
crine signaling to the native heart tissue (Central
Illustration). As our understanding of exosomal
biology advances, patches can be engineered to opti-
mize this signaling for cardiac regeneration. Use of
genome-editing technologies may further enhance the
potency and functional integration of delivered cells.Major challenges will be to address the potential
arrhythmogenicity risks associated with a large graft.
With exciting translational prospects ahead, future
studies to optimize engineered cardiac tissue thera-
pies in large animals and decipher the mechanisms of
action are fully warranted.
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